News | July 04, 2021
Laurus receives license to manufacture and market 2DG
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Subscribe To Our Newsletter & Stay Updated
